Rogério Gaspar
Rogério Gaspar
CurrentVice-Rector at Universidade de Lisboa (ULisboa)
Emailrgaspar@ff.ul.pt

Rogério Gaspar, obtained his PhD in Pharmaceutical Sciences from the Catholic University of Louvain (Belgium) in 1991 (Pharmacist from the University of Coimbra,Portugal,1985). Started in 1993 a new research group (Colloidal Drug Carriers Unit) within the Centre for Neurosciences and Cell Biology at Coimbra. In the period 1995 to 2002, in parallel with his research activities at academia, he was involved at different levels on the European Regulatory System for Medicinal Products. From 1995 as an expert and member of the national evaluation board and of the CPMP (now CHMP, at European Medicines Agency, EMA); between January 2000 to July 2002 he was Vice-chairman of the Management Board of INFARMED (Portuguese medicines regulator) and member of the Management Board of the European Medicines Agency (EMEA) – also member of committees and expert groups at the European Council of Ministers and European Commission. From 2002 to 2008 was a external consultant within a pharmaceutical company and consultant to ASEAN countries (2005-2006 in a EU cooperation programme). From 2008 to 2011 he returned to regulation at the Portuguese national regulatory authority in medicines (INFARMED), and in 2009/11 as invited member of the newly formed Ad-hoc expert group in Nanotechnology of the European Medicines Agency. Also involved in the several Nanomedicine coordination activities of the European Science Foundation (ESF) as expert or group member (2003-2011).
Currently a Full Professor and Vice-Rector at the University of Lisbon. Since 2007 served as Head of its Pharmaceutical Technology Department and of the research group Nanomedicine & Drug Delivery Systems group at the Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL, co-founded in 2007).2012/2013 served also as Vice-Dean at the FFUL. Rogério Gaspar has (2009-2013) served as a member of the Executive Committee of the European Federation for Pharmaceutical Sciences (EUFEPS), Vice-President (Science Policy & Regulatory Science) in 2011-2012.
Current research interests of his group regard the development of new therapeutic strategies using liposomes, polymeric biodegradable nanoparticles, and polymer therapeutics. His main focus in research is currently oriented towards cytosolic delivery of nucleic acids and use of targeted delivery systems for combination therapy in cancer. Is research group is currently focused in aspects related to intracellular trafficking modulation for advanced drug delivery.